TAK-951 / Takeda - LARVOL DELTA

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Takeda

New P1 trial • Rare Diseases

A Study of TAK-951 in Healthy Adults (clinicaltrials.gov) - P1 | N=48 | Terminated | Sponsor: Takeda

New P1 trial

A Study of TAK-951 in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Takeda | N=138 ➔ 32

Enrollment change

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: Takeda | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Mar 2022 | Trial primary completion date: Dec 2022 ➔ Mar 2022

Trial completion • Trial completion date • Trial primary completion date

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Takeda | Trial completion date: Jan 2022 ➔ Dec 2022 | Trial primary completion date: Jan 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Takeda; N=160 ➔ 100

Clinical • Enrollment change

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery (clinicaltrials.gov) - P2; N=160; Recruiting; Sponsor: Takeda; N=100 ➔ 160

Clinical • Enrollment change

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Takeda; Trial primary completion date: Jul 2021 ➔ Nov 2021

Clinical • Trial primary completion date

A Study of TAK-951 in Healthy Adults (clinicaltrials.gov) - P1; N=138; Completed; Sponsor: Takeda; Recruiting ➔ Completed; N=40 ➔ 138

Clinical • Enrollment change • Trial completion

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Takeda; Trial completion date: Apr 2021 ➔ Aug 2021; Trial primary completion date: Apr 2021 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date

TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Takeda; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open

TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Takeda; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Takeda; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study to Evaluate the Safety,Tolerability, and Pharmacokinetics (PK) of TAK-951 in Healthy Participants Following Intravenous Administration (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Takeda; Not yet recruiting ➔ Recruiting; Trial completion date: Jan 2021 ➔ Apr 2021; Trial primary completion date: Jan 2021 ➔ Apr 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date

TAK-951 Versus Ondansetron in Prophylaxis for Postoperative Nausea and Vomiting in High-Risk Participants (clinicaltrials.gov) - P2; N=100; Not yet recruiting; Sponsor: Takeda

Clinical • New P2 trial

A Study to Evaluate the Safety,Tolerability, and Pharmacokinetics (PK) of TAK-951 in Healthy Participants Following Intravenous Administration (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Takeda

Clinical • New P1 trial